User talk:Luther Burgsvik/sandbox

Dr Michael Yeadon is the former Chief Science Officer and Vice President for the Allergy and Respiratory research Department of Pfizer Global R&D, and the co-Founder of Ziarco Pharma Ltd.

Early Life & Education
In 1981 Michael went to the University of Surrey where he got a First Class degree in Biochemistry Toxicology Pharmacology. He then went on to study for a doctorate, and in 1988 receieved a PhD in Pharmacology studying 'the CNS and peripheral pharmacology of the effects of opioids on respiration.'

Career
He joined Wellcome Research Laboratories in 1988, and worked with Honduran-British pharmacologist Salvador Moncada. He was the first to detect exhaled Nitrous Oxide in animals and later to induce NOS in lung via allergic triggers.

When the Wellcome Research Laboratory closed in 1995, Michael joined Pfizer as the Chief Scientific Officer for their Allergy & Respiratory research department.

Michael was an initiating member of the team that led to the Spiriva Alliance (with Boehringer Ingelheim), which is now the most-prescribed agent for COPD (Chronic Obstructive Pulmonary Disease). Between 2005 and 2006 he became the Vice President in addition to being the Chief Science Officer for the Allergy & Respiratory Diseases research department. In 2011 he left Pfizer, and in 2012 co-founded Ziarco Pharma Ltd with ex-Pfizer colleagues Steve Liu and Lynn Purkins. After securing funding from multiple sources including Biotechnology Value Fund and Pfizer Venture Investments he and his team developed novel & differentiated therapies for inflammatory and allergic diseases. . One of these being an histamine H4 receptor antagonist (for the treatment of eczma). One study showed that it led to a clinically and statistically significant reduction of eczema after eight weeks as measured by the EASI (Eczema Area and Severity Index). In Spring 2018, Michael retired from Ziarco Pharma Ltd due to medical issues.

Personal Life
Michael currently lives in Kent with his wife.

Journal Articles
40 full papers, including: The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis, (2012) Medicinal Chemistry Communication Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2 for the Treatment of Asthma, (2011) Journal of Pharmacology and Experimental Therapeutics Uptake, Efficacy, and Systemic Distribution of Naked, Inhaled Short Interfering RNA (siRNA) and Locked Nucleic Acid (LNA) Antisense, (2011) Molecular Therapy  Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma (2011), Bioorganic & medicinal chemistry letters  Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease, (2011), Journal of Medicinal Chemistry 63 abstracts.

Books
New and Exploratory Therapeutic Agents for Asthma (Lung Biology in Health and Disease)